Answers are grounded in this paper and cite their sources.
A surge of recent studies have identified B cells as pivotal contributors to shaping the tumor microenvironment (TME) within solid tumors. B cells can both directly and indirectly antagonize tumor growth via antibody production, antigen presentation, and cytokine secretion, potentially through the formation of tertiary lymphoid structures. However, certain B cell states have demonstrated the ability to promote tumor growth via immunoregulatory mechanisms such as the production of immunosuppressive cytokines and the expression of immune checkpoints, both of which dampen T cell–dependent antitumor responses. Here, we discuss the dichotomy of B cell function in solid tumors, underscoring both the pro- and antitumor roles that B cells play in the TME. Furthermore, we summarize ongoing efforts to reprogram protumorigenic B cells and/or to promote the activity and abundance of effector B cells as potential immunotherapy approaches in solid tumors.
No takes yet. Share an insight, caveat, or question.
Silva et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: